Dry eye syndrome (DES) is a condition that occurs when the eyes do not produce enough tears, or when the tears are of poor quality. This can lead to symptoms such as burning, itching, redness, and a feeling of grittiness or sandiness in the eyes. DES is a very common condition, affecting up to 30% of the population. It is more common in women than men, and the risk increases with age.
As per Global Insight services’ assessment, about 50+ prominent pharma and biotech giants are working on 50+ drugs in the Dry Eye Syndrome – pipeline landscape globally. Dry Eye Syndrome Pipeline Insight, 2023” report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31207
Dry eye syndrome ( keratoconjunctivitis sicca) is a chronic progressive condition due to lack of moisture and lubrication, resulting in constant irritation of the surface of the eye.
Dry eyes are caused many reasons that disrupt the healthy tear film. Reasons for tear film dysfunction are include hormone changes, autoimmune disease, inflamed eyelid glands or allergic eye disease. Decreased tear production and increased tear evaporation can also be the cause of dry eye.
Report Highlights
Global Insight Service’s, Dry Eye Syndrome – Drug Pipeline Landscape, 2023 report provides an overview of the Dry Eye Syndrome pipeline drugs. This report covers detailed insights on Dry Eye Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Dry Eye Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700